Michael Landsittel Blueprint Medicines Corp (BPMC) insider trading activity

BPMC Quotes by TradingView

Michael Landsittel is Chief Financial Officer of Blueprint Medicines Corp. Currently has a direct ownership of 0 shares of BPMC, which is worth approximately $0. The most recent transaction as insider was on Jul 17, 2025, when has been sold 51,102 shares (Common Stock) at a price of $0.0 per share, resulting in proceeds of $0. This information was disclosed in a Form 4 filing with the Securities and Exchange Commission (SEC).

Shares Held (Direct Ownership) 0
100.0% 3M change
100.0% 12M change
Total Value Held $0

Michael Landsittel Transaction History

Date Transaction Value Shares Traded Shares Held Form
Jul 17 2025
SELL
Sale (or disposition) back to the issuer
-
51,102 Reduced 54.2%
43,175 Common Stock
Jul 17 2025
SELL
Disposition due to a tender of shares in a change of control transaction
-
43,175 Reduced 100.0%
0 Common Stock
Jul 17 2025
BUY
Grant, award, or other acquisition
-
21,353 Added 18.47%
94,277 Common Stock
Mar 05 2025
SELL
Open market or private sale
$469,219 $88.8 p/Share
5,284 Reduced 6.76%
72,924 Common Stock
Mar 01 2025
BUY
Grant, award, or other acquisition
-
11,000 Added 12.33%
78,208 Common Stock
Aug 15 2024
SELL
Open market or private sale
$419,869 $95.23 p/Share
4,409 Reduced 6.16%
67,208 Common Stock
May 15 2024
SELL
Open market or private sale
$411,411 $106.86 p/Share
3,850 Reduced 5.1%
71,617 Common Stock
May 08 2024
BUY
Exercise of conversion of derivative security
$150,486 $5.34 p/Share
28,181 Added 27.19%
75,467 Common Stock
May 02 2024
SELL
Open market or private sale
$1,050,000 $105.0 p/Share
10,000 Reduced 17.46%
47,286 Common Stock
May 02 2024
BUY
Exercise of conversion of derivative security
$360,500 $36.05 p/Share
10,000 Added 14.86%
57,286 Common Stock
Mar 28 2024
SELL
Open market or private sale
$475,000 $95.0 p/Share
5,000 Reduced 9.56%
47,286 Common Stock
Mar 28 2024
BUY
Exercise of conversion of derivative security
$180,250 $36.05 p/Share
5,000 Added 8.73%
52,286 Common Stock
Mar 15 2024
SELL
Open market or private sale
$1,209,416 $88.06 p/Share
13,734 Reduced 22.51%
47,286 Common Stock
Mar 15 2024
BUY
Exercise of conversion of derivative security
$180,250 $36.05 p/Share
5,000 Added 7.57%
61,020 Common Stock
Mar 07 2024
SELL
Open market or private sale
$453,722 $90.69 p/Share
5,003 Reduced 8.2%
56,020 Common Stock
Mar 01 2024
BUY
Grant, award, or other acquisition
-
12,500 Added 17.0%
61,023 Common Stock
Mar 06 2023
SELL
Open market or private sale
$135,615 $45.1 p/Share
3,007 Reduced 5.84%
48,523 Common Stock
Mar 01 2023
BUY
Grant, award, or other acquisition
-
12,500 Added 19.52%
51,530 Common Stock
Mar 07 2022
SELL
Open market or private sale
$58,831 $56.19 p/Share
1,047 Reduced 2.61%
39,030 Common Stock
Mar 03 2022
SELL
Open market or private sale
$80,039 $60.27 p/Share
1,328 Reduced 3.21%
40,077 Common Stock
Mar 01 2022
BUY
Grant, award, or other acquisition
-
12,500 Added 23.19%
41,405 Common Stock
Mar 04 2021
SELL
Open market or private sale
$132,315 $87.8 p/Share
1,507 Reduced 4.96%
28,905 Common Stock
Mar 01 2021
BUY
Grant, award, or other acquisition
-
13,062 Added 30.05%
30,412 Common Stock
ML

Michael Landsittel

Chief Financial Officer
Cambridge, MA

Track Institutional and Insider Activities on BPMC

Follow Blueprint Medicines Corp and customize your updates to receive the information that matters most to you.

Institutional Portfolio Updates

Receive a notification when an Institution or Guru buys or sells BPMC shares.

Notify only if

Insider Trading

Get notified when an Blueprint Medicines Corp insider buys or sells BPMC shares.

Notify only if

News

Receive news related to Blueprint Medicines Corp

Choose your preferred platform and Sign Up 👇 Telegram Email
Track Activities on BPMC